<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) is the most common cause of acquired <z:hpo ids='HP_0100724'>thrombophilia</z:hpo>, but experimental and clinical evidence accumulated over the years suggest that the clinical manifestations of APS go beyond those of a simple <z:e sem="disease" ids="C0398623" disease_type="Disease or Syndrome" abbrv="">hypercoagulable state</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Although still a controversial topic, the elevated risk of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> in <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> seems little accounted for by the presence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>, whereas <z:hpo ids='HP_0004416'>premature atherosclerosis</z:hpo> has been addressed in few series of patients with primary APS </plain></SENT>
<SENT sid="2" pm="."><plain>The available data in primary APS suggest that traditional risk factors for <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> are less involved in <z:e sem="disease" ids="C0852949" disease_type="Disease or Syndrome" abbrv="">arterial disease</z:e>, rather <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> appear as major players </plain></SENT>
<SENT sid="3" pm="."><plain>Their effect on the coagulation system, the vessel wall and on the <z:chebi fb="11" ids="22586">antioxidant</z:chebi>/oxidant balance impairs vascular homeostasis, leading to premature arterial thickening </plain></SENT>
</text></document>